Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Available source content was suppressed because validation identified a conflict.

Standard Care

Core clinician-reference fields are available or not applicable.

Participants treated with tirzepatide for weight management.

Tirzepatide Treatment

In SURMOUNT-1, 81.8 % of participants treated with tirzepatide (pooled 10 mg/15 mg) shifted at least one BMI category lower.

Participants receiving standard care for obesity management.

The SURMOUNT clinical trials assessed in these analyses were SURMOUNT-1 (NCT04184622) and SURMOUNT-4 (NCT04660643).

Authoritative quality diagnostic: invalid or missing unit.

Authoritative quality diagnostic: invalid or missing value.

Tirzepatide improves cardiometabolic health in obesity.

Not extracted from the authoritative source.

Clinician-reference record is usable with limitations in: arms, comparator.

Tirzepatide improves diabetes management during Ramadan fasting

Comparator Interventions

Participants received once-weekly tirzepatide treatment.

Participants were randomly assigned to receive once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) or one of the following comparator interventions: semaglutide (1 mg), insulin degludec, or placebo.

Participants received either semaglutide, insulin degludec, or placebo.

Tirzepatide × Fasting Plasma Glucose (FPG)

Available supporting studies

Tirzepatide improves cardiometabolic health in obesity.

Tirzepatide improves diabetes management during Ramadan fasting

Tirzepatide improves glycemic control in early-onset type 2 diabetes